Legal Action News

Your news source for lawsuits and other civil legal matters

Legal Action Recently...

April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
March 2006
February 2006
January 2006
December 2005
November 2005
October 2005
September 2005
August 2005
July 2005
June 2005
May 2005
April 2005
March 2005
February 2005
January 2005
December 2004


Legal Action News RSS Feed
RSS Feed



 

Eli Lilly and Company Announces Approvable Letter Issued by FDA and Pfizer Wins Lawsuit

28 August 2006

Pharmaceuticals Instruments industry news provided by Financial News USA (OTC: FNWU). Eli Lilly and Company (NYSE:LLY) announced recently that it received an approvable letter from the U.S. Food and Drug Administration (FDA) for ruboxistaurin mesylate (proposed trade name Arxxant(TM), pronounced, ark-ZONT), its investigational oral therapy being studied for treatment of diabetic retinopathy (DR), a diabetic eye disease. Arxxant is an investigational therapy for the treatment of moderate to severe non-proliferative diabetic retinopathy. At the suggestion of CytoDyn, Inc. (OTCBB:CYDY), Joe Trujillo, a senior field representative for U.S. Senator Pete Domenici (R-NM), spent a portion of his summer vacation at the XVI World AIDS Conference held in Toronto from August 12 through August 16, 2006. Trujillo met with several of the U.S. citizens who continue to suffer from the cancers, opportunistic infections, and other medical conditions that characterize AIDS despite much progress in treating the disease.


Drug maker Pfizer Inc. (NYSE:PFE) said Thursday a federal jury ruled it did not infringe on a U.S. patent owned by Synthon IP covering a process used to make the active ingredient in a hypertension drug. The jury in federal court in the Eastern District of Virginia ruled unanimously in favor of Pfizer, the company said. The dispute focused on Synthon's patent for amlodipine, the active ingredient in Pfizer's hypertension drug Norvasc. Schering-Plough Corporation (NYSE: SGP) announced recently clarification on its question regarding the expiration date for its rights to market golimumab worldwide, excluding the United States, Japan and certain other Asian markets. As announced in August 2005, Schering-Plough and Centocor, Inc. stated that they were working together to move forward with their collaboration on golimumab and were taking steps to resolve the difference of opinion as to the expiration date.


About Financial News USA


Financial News USA is a Next Generation Financial Communications firm focused on the distribution of market moving news. Financial News USA has developed leading edge e-publishing tools including programming proprietary RSS feeds and enabling open source press release publishing across its network. Financial News USA has been aggressively expanding its news distribution network by targeting direct feeds to financial news and data providers such as FinancialContent, Yahoo (NASDAQ: YHOO), among others. Financial News USA offers a free news feed available online (www.financialnewsusa.com) to websites and financial services looking for content and for individual investors looking to stay informed on the financial markets. Financial News USA and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.financialnewsusa.com Contact Information:


Financial News USA


Tel: (626) 961-8041


Email: info@financialnewsusa.com

Source: financialnewsusa


All trademarks and copyrighted information contained herein are the property of their respective owners.


Related Articles


 
Law News



A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z